Showing 1 - 10 of 70
Case review 10/12/2019
Our product liability and life sciences team recently hosted their fifth life sciences conference which focused on emerging risks in innovative healthcare technology.
The UK is the second least supportive nation in their attitude towards the development of unmanned vessels, according to our study across six territories (United Kingdom, United States, Australia, China, Singapore and Hong Kong), and the least supportive of autonomous vehicles more generally.
Lab-grown meat is not just the latest product for environmentally conscious consumers, it also heralds a new type of agriculture and food product design, which could offer attractive risk profiles for insurers that get to know the science.
Case review 14/11/2019
In Bailey & Ors v GlaxoSmithKline “The Seroxat Group Litigation” [08.11.19] the Court of Appeal decided that it was impermissible for the claimants to expand the scope of their pleaded case at trial, which was previously determined at both the case management stage and during the pre-trial review.
Case review 30/10/2019
Supreme Court unanimously concludes that insurers were not liable to pay the uninsured claimants’ costs
Today, the Supreme Court has sensibly overturned the decisions of the lower courts in Travelers in concluding that Travelers’ conduct did not cross the line into ‘unjustified intermeddling’ (per TGA Chapman Limited v Christopher ) in litigation to which it was not a party.
With the current Article 50 extension deadline of 31 October 2019 looming against a complex and uncertain political backdrop, and talks between the UK and EU continuing without any clear sign of a definitive outcome, the possibility of a no-deal Brexit remains at an all-time high.
Boris Johnson’s first Queen’s Speech delivered on Monday 14 October 2019 - dominated by Brexit-related legislation - included the Medicines and Medical Devices Bill (the Bill).
Following today's Queen's Speech, we have officially responded to some key domestic legislation relating Air Traffic Management and Unmanned Aircraft Bill, and the Medicines and Medical Devices Bill.
In a week that is likely to be dominated by ongoing Brexit negotiations and timelines, we have today been provided with this Government’s priorities and legislative programme in the Queen’s Speech which took place this morning.